SCHEMBL24253534

SCHEMBL24253534

CC(C)Cc1ccc2c(c1Cl)CCN(C)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
DRD2 P14416 3/20 0.42
DRD1 P21728 3/20 0.42
DRD5 P21918 3/20 0.42
DRD3 P35462 2/20 0.42
DRD4 P21917 1/20 0.42
HTR2A P28223 1/20 0.40
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
ADRA2A P08913 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
ADRA1D P25100 2/20 0.37
ADRA1A P35348 2/20 0.37
ADRA1B P35368 2/20 0.37
CYP2D6 P10635 1/20 0.37
KAT2B Q92831 1/20 0.37
BRD9 Q9H8M2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253475 0.85 HTR2C (0.42) HTR2CHTR2BDRD2DRD1DRD5
SCHEMBL22993617 0.83 HTR2C (0.47) HTR2CHTR2BDRD2DRD1DRD5
SCHEMBL25444509 0.79 MAOA (0.49) HTR2CHTR2BDRD2DRD1DRD5
SCHEMBL24253232 0.77 DRD2 (0.44) HTR2CHTR2BDRD2DRD1DRD5
SCHEMBL22993446 0.74 DRD2 (0.48) HTR2CHTR2BDRD2DRD1DRD5
SCHEMBL24253492 0.74 KLKB1 (0.33) HTR2CHTR2BHTR2AADRA2AADRA2B
SCHEMBL23774332 0.72 HTR2C (0.52) HTR2CHTR2BHTR2AADRA2AADRA2B
SCHEMBL25091105 0.72 HTR2C (0.40) HTR2CHTR2BHTR2AMAOAMAOB
SCHEMBL14473194 0.70 ADRA2A (0.46) DRD2DRD1DRD5DRD3DRD4
SCHEMBL22993218 0.69 MAOA (0.47) DRD2DRD1DRD5DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 HTR2C 4421/4885HTR2B 2259/4885DRD2 4189/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 HTR2C 4421/4885HTR2B 2259/4885DRD2 4189/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 HTR2C 4421/4885HTR2B 2259/4885DRD2 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.